Hematuria
Conditions
Brief summary
The study is undertaken to investigate if the urethral microtrauma, caused by intermittent catheterization, differs between three hydrophilic catheters for intermittent catheterization, LoFric; SpeediCath (SC) and SpeediCath Compact Male (SCCM). The study is a prospective, randomised, cross-over, single-centre study. Each subject will be randomized to use three different catheter types. Three catheterizations will be performed with each catheter type during one day, with at least two hours between each catheterization. The washout period between catheter switch will be at least one week. The primary objective is to evaluate urethral microtrauma for three hydrophilic catheters with regards to hematuria after intermittent catheterization. The secondary objectives are to evaluate urethral microtrauma for three hydrophilic catheters with regards to pyuria and subjective evaluation after intermittent catheterization. The safety of the three catheters will be evaluated in terms of adverse advents, non-serious and serious, rated for causality. The hypothesis that level of hematuria is equal after using different catheters will be tested using Wilcoxon signed rank test. The hypothesis will be rejected if the p-value is less than 5%.
Interventions
DEVICELoFric
Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
DEVICESpeediCath
Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
DEVICESpeediCath Compact Male
Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
Sponsors
Wellspect HealthCare
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Provision of informed consent 2. Healthy male volunteers aged 18 years and over (half of the included subjects shall be 18-50 years and the other half \>50 years old) 3. Negative urine dipstick test (no blood in the urine) before randomization
Exclusion criteria
1. Intake of anticoagulants at enrolment and during the study period 2. Intake of antibiotics at enrolment and during the study period 3. Urinary tract infection (UTI) at enrolment and during the study period 4. Known abnormalities or diseases of the lower urinary tract with the exception of BPH 5. Kidney stones 6. Tumour in the urinary tract 7. Known Sexually transferable diseases in the urinary tract during the study period 8. Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site) 9. Previous enrolment or randomisation of treatment in the present study 10. Simultaneous participation in another clinical study that might interfere with the endpoints of the study, as deemed by the investigator 11. Severe non-compliance to protocol as judged by the investigator and/or Astra Tech
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hematuria | Approximately 2 hours after last catheterization | Blood in urine (measured by microscopic urine sediment evaluation) will be assessed at the first normal micturition after three catheterizations. Comparison will be made between study catheter/visit days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hematuria | At first, second and third catheterization, approximately 2 hours apart | Blood in urine (measured by microscopic urine sediment evaluation). Comparison will be made between study catheter/visit days. |
| Pyuria | At first, second and third catheterization, approximately 2 hours apart | White blood cells in urine (measured by microscopic urine sediment evaluation). Comparison will be made between study catheter/visit days. |
Countries
Sweden
Outcome results
None listed